Literature DB >> 6319278

5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.

G J Wenting, A J Woittiez, A J Man in't Veld, M A Schalekamp.   

Abstract

The serotonin (5-hydroxytryptamine, 5-HT) antagonist, ketanserin, has a high affinity for 5-HT2-receptors but it also binds to alpha 1-adrenoceptors. The compound (10 mg i.v.) lowered mean arterial pressure by 22% +/- 2% (mean +/- SEM, p less than 0.001) in 30 patients with essential hypertension. Measurements of heart rate, cardiac output, cardiac filling pressures, forearm blood flow, renal blood flow, and glomerular filtration rate revealed a hemodynamic pattern compatible with vasodilation of both resistance and capacitance vessels. This was accompanied by moderate reflex cardiostimulation. Ketanserin did not alter the pressor effect of bolus injections of (-)-phenylephrine hydrochloride (25, 50, 100, and 200 micrograms i.v.). Ketanserin also had a distinct hypotensive effect in four normotensive patients with autonomic insufficiency due to an efferent sympathetic lesion, who were unresponsive to phentolamine (20 mg i.v.). Thus, ketanserin in the dose we have used appears to lower blood pressure independently of alpha 1-adrenoceptor blockade. On the other hand, in patients with essential hypertension the antihypertensive effect of ketanserin was blunted by pretreatment with prazosin (12 mg/day). Therefore, a certain degree of alpha 1-adrenergic tone seems to be required for the compound to exert its full antihypertensive action. The findings are indirect evidence for a role of 5-HT in the maintenance of increased vascular resistance in essential hypertension. This may be related, at least in part, to the alleged amplifying effect of 5-HT on alpha 1-adrenoceptor-mediated vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319278     DOI: 10.1161/01.hyp.6.1.100

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  26 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Effect of the acute sublingual administration of ketanserin in hypertensive patients.

Authors:  G Aliberti; E D'Erasmo; C M Oddo; E Vecci
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

3.  Antihypertensive treatment with ketanserin shows no evidence of vascular serotonin2-receptor and alpha 1-adrenoceptor blockade.

Authors:  G J Blauw; C J Doorenbos; T A Bruning; P van Brummelen; P A van Zwieten
Journal:  Drugs       Date:  1990       Impact factor: 9.546

4.  Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.

Authors:  J J Kunnen; H P Dahler; J G Doorenspleet; J C van Oene
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Ketanserin in the treatment of diabetes-associated hypertension.

Authors:  C Beretta-Piccoli
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Haemodynamic changes associated with long term antihypertensive therapy with ketanserin.

Authors:  H Noda; M Isaka; Y Ito; T Fujita
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin.

Authors:  J C van Oene
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  Effects of ketanserin on systemic and regional haemodynamics in patients with essential hypertension.

Authors:  Y Ito; M Isaka; H Noda; Y Sato; T Fujita
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  The relevance of serotonin antagonism in the treatment of hypertension.

Authors:  A E Doyle
Journal:  Drugs       Date:  1988       Impact factor: 9.546

10.  Pharmacokinetics of ketanserin in patients with essential hypertension.

Authors:  B Persson; A Pettersson; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.